Regulatory B and T cell responses in patients with autoimmune thyroid disease and healthy controls

Danish Medical Journal

Volumn 63, Issue 2, 2016, Pages

  Kristensen, Birte ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

CD14 ANTIGEN; CD19 ANTIBODY; CD24 ANTIGEN; CD27 ANTIGEN; CD28 ANTIGEN; CD3 ANTIBODY; CD38 ANTIGEN; CD4 ANTIBODY; CD44V ANTIGEN; CD45 ANTIGEN; CD5 ANTIGEN; CPG OLIGODEOXYNUCLEOTIDE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 35; INTERLEUKIN 4; INTERLEUKIN 6; IONOMYCIN; IXEKIZUMAB; LEUKOSIALIN; PHORBOL 13 ACETATE 12 MYRISTATE; SECUKINUMAB; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; AUTOANTIBODY; AUTOANTIGEN; THYROGLOBULIN; THYROTROPIN RECEPTOR;

ANTIGEN PRESENTING CELL; ARTICLE; AUTOIMMUNE THYROIDITIS; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CELL STIMULATION; CELLULAR IMMUNITY; ESCHERICHIA COLI; GRAVES DISEASE; HASHIMOTO DISEASE; HELPER CELL; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNE RESPONSE; PERIPHERAL BLOOD MONONUCLEAR CELL; REGULATORY T LYMPHOCYTE; TH1 TH2 BALANCE; TH17 CELL; BLOOD; CASE CONTROL STUDY; CELL DIFFERENTIATION; IMMUNOLOGY; METABOLISM; REGULATORY B LYMPHOCYTE;

AUTOANTIBODIES; AUTOANTIGENS; B-LYMPHOCYTES, REGULATORY; CASE-CONTROL STUDIES; CELL DIFFERENTIATION; GRAVES DISEASE; HASHIMOTO DISEASE; HUMANS; INTERLEUKIN-10; RECEPTORS, THYROTROPIN; T-LYMPHOCYTES, REGULATORY; TH17 CELLS; THYROGLOBULIN;

EID: 84956847008     PISSN: None     EISSN: 22451919     Source Type: Journal    
DOI: None     Document Type: Article

References (330)

1. Sinha A, Lopez M, McDevitt H. Autoimmune diseases: the failure of self tolerance. Science. 1990 Jun 15;248:1380-8.
2. Stassi G, De Maria R. Autoimmune thyroid disease: new models of cell death in autoimmunity. Nat Rev Immunol. 2002 Mar;2:195-204.
3. Goodnow CC, Sprent J, Fazekas de St Groth B, Vinuesa CG. Cellular and genetic mechanisms of self tolerance and autoim-munity. Nature. 2005 Jun 2;435:590-7.
4. Palmer E. Negative selection-clearing out the bad apples from the T-cell repertoire. Nat Rev Immunol. 2003 May;3:383-91.
5. Smilek DE, Ehlers MR, Nepom GT. Restoring the balance: immunotherapeutic combinations for autoimmune disease. Dis Model Mech. 2014 May;7(5):503-13.
6. Starr TK, Jameson SC, Hogquist KA. Positive and negative selection of T cells. Annu Rev Immunol. 2003 Jan;21:139-76.
7. Hogquist KA, Baldwin TA, Jameson SC. Central tolerance: learning self-control in the thymus. Nat Rev Immunol. 2005 Oct;5:772-82.
8. Tobón GJ, Izquierdo JH, Cañas CA. B lymphocytes: develop- ment, tolerance, and their role in autoimmunity-focus on systemic lupus erythematosus. Autoimmune Dis. 2013 Jan;2013:827254.
9. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Pillars article: immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoim- mune diseases. J Immunol. 1995 Apr 1;155:1151-64.
10. Roncarolo MG, Bacchetta R, Bordignon C, Narula S, Lev- ings M. Type 1 T regulatory cells. Immunol Rev. 2001;182:68-79.
11. Mizoguchi A, Bhan A. A Case for Regulatory B Cells. J Immunol. 2006 Jan 3;176:705-10.
12. Mauri C, Ehrenstein MR͘ The “short” history of regulatory B cells. Trends Immunol. 2008 Jan;29:34-40.
13. Bluestone JA. Mechanisms of tolerance. Immunol Rev. 2011 May;241:5-19.
14. Júnior DM, Araújo JAP, Catelan TTT, de Souza AWS, Cruvinel W de M, Andrade LEC, et al. Immune System - Part II Basis of the immunological response mediated by T and B lymphocytes. Bras J Rheumatol. 2010;50:552-80.
15. Abbas A, Murphy K, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787-93.
16. Crome S, Wang A, Levings M. Translational mini-review se-ries on Th17 cells: function and regulation of human T helper 17 cells in health and disease. Clin Exp Immunol. 2009 Feb;159:109–19.
17. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coff man RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986 Jul 1;136:2348-57.
18. Mosmann TR, Coffman R͘ THI ND TH2 CELLS : Different Patterns of Lymphokine Functional Properties. Annu Rev Immunol. 1989;7:145-73.
19. Del Prete G, Romagnani S. The role of TH1 and TH2 sub- sets in human infectious diseases. Trends Microbiol. 1994 Jan;2:4-6.
20. Romagnani S. The Th1/Th2 paradigm. Immunol Today. 1997 Jun;18:263-6.
21. Szabo S, Kim S, Costa G, Zhang X, Fathman C, Glimcher L. A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell. 2000 Mar 17;100:655-69.
22. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood. 2008 Sep 1;112:1557-69.
23. Annunziato F, Romagnani S. Heterogeneity of human effector CD4+ T cells. Arthritis Res Ther. 2009 Jan;11:257.
24. Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, Kashiwamura S, et al. Essential role of Stat6 in IL-4 signalling. Nature. 1996;380:627-30.
25. Zhu J, Guo L, Watson CJ, Hu-Li J, Paul WE. Stat6 Is Neces- sary and Sufficient for IL-4’s Role in Th2 Differentiation and Cell Expansion. J Immunol. 2001 Jun 15;166:7276-81.
26. Le Gros G, Ben-Sasson S, Seder R, Finkelman F, Paul W. Generation of interleukin 4 (IL-4)-producing cells in vivo and in vitro: IL-2 and IL-4 are required for in vitro generation of IL- 4-producing cells. J Exp Med. 1990;172:921-9.
27. Swain SL, Weinberg A, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. J Immunol. 1990 Dec 1;145:3796-806.
28. Fishman M, Perelson A. Th1/Th2 Cross Regulation. J Theor Biol. 1994;170:25-6.
29. Hwang ES, Szabo SJ, Schwartzberg PL, Glimcher LH. T helper cell fate specified by kinase-mediated interaction of T- bet with GATA-3. Science. 2005 Jan 21;307:430-3.
30. Usui T, Nishikomori R, Kitani A, Strober W. GATA-3 sup- presses Th1 development by downregulation of Stat4 and not through effects on IL-12Rbeta2 chain or T-bet. Immunity. 2003 Mar;18:415-28.
31. Usui T, Preiss JC, Kanno Y, Yao ZJ, Bream JH, O’Shea JJ, et al. T-bet regulates Th1 responses through essential effects on GATA-3 function rather than on IFNG gene acetylation and transcription. J Exp Med. 2006 Mar 20;203:755-66.
32. Romagnani S. Regulation of the development of type 2 T- helper cells in allergy. Curr Opin Immunol. 1994 Dec;6:838-46.
33. Aggarwal S, Ghilardi N, Xie M-H, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003 Jan 17;278:1910-4.
34. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, Murphy KM, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol. 2005 Nov;6:1123-32.
35. Annunziato F, Cosmi L, Liotta F, Maggi E, Romagnani S. De- fining the human T helper 17 cell phenotype. Trends Immu- nol. Elsevier Ltd; 2012 Oct;33:505-12.
36. Afzali B, Lombardi G, Lechler R, Lord G. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol. 2007 Apr;148:32-46.
37. Tesmer LA, Lundy SK, Sarkar S, Fox DA. Th17 cells in human disease. Immunol Rev. 2008;223:87-113.
38. Kurts C. Th17 cells: a third subset of CD4+ T effector cells involved in organ-specific autoimmunity. Nephrol Dial Transplant. 2008 Mar;23:816-9.
39. Shi Y, Wang H, Su Z, Chen J, Xue Y, Wang S, et al. Differentiation Imbalance of Th1/ Th17 in Peripheral Blood Mononuclear Cells Might Contribute to Pathogenesis of Hashimoto’s Thyroiditis. Scand J Immunol. 2010;72:250-5.
40. Nanba T, Watanabe M, Inoue N, Iwatani Y. Increases of the Th1-Th2 Cell Ratio in Severe Hashimoto’s Disease and in the Proportion of Th17 Cells in Intractable Graves’ Disease͘ Thyroid. 2009;19:495-501.
41. Figueroa-Vega N, Alfonso-Pérez M, Benedicto I, Sánchez- Madrid F, González-Amaro R, Marazuela M. Increased circulating pro-inflammatory cytokines and Th17 lymphocytes in Hashimoto’s thyroiditis͘ J Clin Endocrinol Metab. 2010 Feb;95:953-62.
42. Yang L, Anderson DE, Baecher-Allan C, Hastings WD, Bet- telli E, Oukka M, et al. IL-21 and TGF-beta are required for dif- ferentiation of human T(H)17 cells. Nature. 2008 Jul 17;454:350-2.
43. Acosta-Rodriguez E V, Napolitani G, Lanzavecchia A, Sal- lusto F. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol. 2007 Sep;8:942-9.
44. Manel N, Unutmaz D, Littman DR. The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat. Nat Immunol. 2008 Jun;9:641-9.
45. Wilson NJ, Boniface K, Chan JR, McKenzie BS, Blu- menschein WM, Mattson JD, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol. 2007 Sep;8:950-7.
46. Volpe E, Servant N, Zollinger R, Bogiatzi SI, Hupé P, Barillot E, et al. A critical function for transforming growth factor beta, interleukin 23 and proinflammatory cytokines in driving and modulating human T(H)-17 responses. Nat Immunol. 2008 Jul;9:650-7.
47. O’Garra, Stockinger B, Veldhoen M͘ Differentiation of human TH -17 cells does require TGF- β ! Nat Immunol. 2008;9:588-90.
48. Santarlasci V, Maggi L, Capone M, Frosali F, Querci V, De Palma R, et al. TGF-beta indirectly favors the development of human Th17 cells by inhibiting Th1 cells. Eur J Immunol. 2009 Jan;39:207-15.
49. Ivanov II, McKenzie BS, Zhou L, Tadokoro CE, Lepelley A, Lafaille JJ, et al. The orphan nuclear receptor RORgammat di- rects the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006 Sep 22;126:1121-33.
50. Unutmaz D. RORC2: the master of human Th17 cell programming. Eur J Immunol. 2009 Jun;39:1452-5.
51. Park H, Li Z, Yang X, Chang S, Nurieva R, Wang Y, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol. 2005;6:1133-41.
52. Acosta-Rodriguez E V, Rivino L, Geginat J, Jarrossay D, Gat- torno M, Lanzavecchia A, et al. Surface phenotype and anti- genic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol. 2007;8:639-46.
53. Bluestone JA, Abbas AK. Natural versus adaptive regulatory T cells. Nat Rev Immunol. 2003 Mar;3:253-7.
54. Horwitz DA, Zheng SG, Gray JD. Natural and TGF-beta-in- duced Foxp3(+)CD4(+) CD25(+) regulatory T cells are not mirror images of each other. Trends Immunol. 2008 Sep;29:429-35.
55. Khattri R, Cox T, Yasayko S-A, Ramsdell F. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol.2003 Apr;4:337-42.
56. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003 Apr;4:330-6.
57. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003 Feb 14;299:1057-61.
58. Ramsdell F, Celltech R. Foxp3 and Natural Regulatory T Cells : Key to a Cell Lineage ? Immunity͘ 2003;19:165-8
59. Sakaguchi S, Wing K, Onishi Y, Prieto-Martin P, Yamaguchi T. Regulatory T cells: how do they suppress immune responses? Int Immunol. 2009 Oct;21:1105-11.
60. Krummel MF, Allison JP. CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation. J Exp Med. 1995;182:459-65.
61. Saito T. Negative regulation of T cell activation. Curr Opin Immunol. 1998;10:313-21.
62. Lanier LL, Fallon SO, Somoza C, Phillips JH, Linsley PS, Oku- mura K, et al. CD80 (B7) and CD86 (B70) provide similar cost- imulatory signals for T cell proliferation, cytokine production and generation of CTL. J Immunol. 1995;154:97-105.
63. Fontenot JD, Rasmussen JP, Gavin MA, Rudensky AY. A function for interleukin 2 in Foxp3-expressing regulatory T cells. Nat Immunol. 2005 Nov;6:1142-51.
64. Thornton A, Donovan E, Piccirillo C, Shevach E. Cutting Edge: IL-2 Is Critically Required for the In Vitro Activation of CD4+CD25+ T Cell Suppressor Function. J Immunol. 2004 May 20;172:6519-23.
65. Thornton AM, Shevach EM. CD4+CD25+ Immunoregulatory T cells suppress polyclonal T cell activation in vitro by in- hibiting interleuki 2 production. J Exp Med. 1998;188:287-96.
66. Cottrez F, Groux H. Specialization in tolerance: innate CD4+CD25+ versus acquired TR1 and TH3 regulatory T cells. Transplantation. 2004 Jan 15;77:S12-S15.
67. Groux H, O’Garra, Bigler M, Rouleau M, ntonenko S, de Vries JE, et al. A CD4+ T-cell subset inhibits responses and prevents colitis. Nature. 1997;389:737-42.
68. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev. 2006 Aug;212:28-50.
69. Foussat A, Cottrez F, Brun V, Fournier N, Breittmayer J, Groux H. A Comparative Study between T Regulatory Type 1 and CD4+CD25+ T Cells in the Control of Inflammation. J Immunol. 2003 Nov 7;171:5018-26.
70. Bilate AM, Lafaille JJ. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu Rev Immunol. 2012 Jan;30:733-58.
71. Levings MK, Gregori S, Tresoldi E, Cazzaniga S, Bonini C, Roncarolo MG. Differentiation of Tr1 cells by immature den- dritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood. 2005 Feb 1;105:1162-9.
72. Groux H, Cottrez F. The complex role of interleukin-10 in autoimmunity. J Autoimmun. 2003 Jun;20:281-5.
73. Kemper C, Chan AC, Green JM, Brett KA, Murphy KM, At- kinson JP. Activation of human CD4+ cells with CD3 and CD46 induces a T-regulatory cell 1 phenotype. Nature. 2003;421:388-92.
74. Sabat R, Grütz G, Warszawska K, Kirsch S, Witte E, Wolk K, et al. Biology of interleukin-10. Cytokine Growth Factor Rev. 2010 Oct;21:331-44.
75. Moore K, de Waal Malefyt R, Robert L, O’Garra Inter- leukin-10 and the Interleukin-10 Receptor. Annu Rev Immu- nol. 2001;19:683-765
76. Howard M, O’Garra, Ishida H, De Waal Malefyt R, De Vries J. Biological properties of interleukin 10. J Clin Immunol. 1992 Mar;12:239-47.
77. Li MO, Wan YY, Sanjabi S, Robertson A-KL, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol. 2006 Jan;24:99-146.
78. Oh SA, Li MO. TGF-β: guardian of T cell function. J Immunol. 2013 Oct 15;191:3973-9.
79. Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of la- bor? Immunity. Elsevier Inc.; 2009 May;30:626-35.
80. Dieckmann D, Plottner H, Berchtold S, Berger T, Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med. 2001 Jun 4;193:1303-10.
81. Green EA, Gorelik L, McGregor CM, Tran EH, Flavell RA. CD4+CD25+ T regulatory cells control anti-islet CD8+ T cells through TGF-beta-TGF-beta receptor interactions in type 1 di- abetes. Proc Natl Acad Sci U S A. 2003 Sep 16;100:10878-83.
82. Collison LW, Pillai MR, Chaturvedi V, Vignali DAA. Regula- tory T cell suppression is potentiated by target T cells in a cell contact, IL-35- and IL-10-dependent manner. J Immunol. 2009 May 15;182:6121-8.
83. Walker MR, Kasprowicz DJ, Gersuk VH, Bènard A, Landeghen M Van, Buckner JH, et al. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4 + CD25- T cells. J Clin Invest. 2003;112:1437-43.
84. Walker MR, Carson BD, Nepom GT, Ziegler SF, Buckner JH. De novo generation of antigen-specific CD4+CD25+ regulatory T cells from human CD4+CD25-cells. Proc Natl Acad Sci USA. 2005;102:4103-8.
85. Zheng SG, Wang JH, Gray JD, Soucier H, Horwitz DA. Natu- ral and Induced CD4+CD25+ Cells Educate CD4+CD25- Cells to Develop Suppressive Activity: The Role of IL-2, TGF-beta, and IL-10. J Immunol. 2004 Apr 20;172:5213-21.
86. Wang J, Ioan-Facsinay A, van der Voort EIH, Huizinga TWJ, Toes REM. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol. 2007 Jan;37:129-38.
87. Torgerson TR, Ochs HD. Immune dysregulation, polyendo crinopathy, enteropathy, X-linked: forkhead box protein 3 mutations and lack of regulatory T cells. J Allergy Clin Immunol. 2007 Oct;120:744-50.
88. Kobayashi I, Shiari R, Yamada M, Kawamura N, Okano M, Yara A, et al. Novel mutations of FOXP3 in two Japanese pa- tients with immune dysregulation, polyendocrinopathy, en- teropathy, X linked syndrome (IPEX). J Med Genet. 2001 Dec;38:874-6.
89. Ryder LR, Bartels EM, Woetmann A, Madsen HO, Odum N, Bliddal H, et al. FoxP3 mRNA splice forms in synovial CD4+ T cells in rheumatoid arthritis and psoriatic arthritis. APMIS. 2012 May;120:387-96.
90. Smith E, Finney H, Nesbitt A, Ramsdell F, Robinson M. Splice variants of human FOXP3 are functional inhibitors of human CD4+ T-cell activation. Immunology. 2006;119:203-11.
91. Allan S, Passerini L, Bacchetta R, Crellin N, Dai M, Orban P, et al. The role of 2 FOXP3 isoforms in the generation of hu- man CD4+ Tregs. J Clin Invest. 2005;115:3276-84.
92. Schubert L, Jeffery E, Zhang Y, Ramsdell F, Ziegler S. Scurfin (FOXP3) acts as a repressor of transcription and regu- lates T cell activation. J Biol Chem. 2001 Oct 5;276:37672-9.
93. Bettelli E, Dastrange M, Oukka M. Foxp3 interacts with nu- clear factor of activated T cells and NF-kappa B to repress cy- tokine gene expression and effector functions of T helper cells. Proc Natl Acad Sci U S A. 2005 Apr 5;102:5138-43.
94. Du J, Huang C, Zhou B, Ziegler S. Isoform-Specific Inhibi- tion of ROR-alpha Mediated Transcriptional Activation by Human FOXP3. J Immunol. 2008 Mar 19;180:4785-92.
95. Zhou L, Lopes JE, Chong MMW, Ivanov II, Min R, Victoria GD, et al. TGF- β -induced Foxp3 inhibits Th17 cell differentia- tion by antagonizing RORγt function. Nature. 2008;453:236-40.
96. Krejsgaard T, Gjerdrum LM, Ralfkiaer E, Lauenborg B, Erik- sen KW, Mathiesen A-M, et al. Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome. Leukemia. 2008 Dec;22:2230-9.
97. Afzali B, Mitchell P, Lechler RI, John S, Lombardi G. Trans- lational mini-review series on Th17 cells: induction of inter- leukin-17 production by regulatory T cells. Clin Exp Immunol. 2009 Feb;159:120-30.
98. Annunziato F, Cosmi L, Santarlasci V, Maggi L, Liotta F, Mazzinghi B, et al. Phenotypic and functional features of human Th17 cells. J Exp Med. 2007;204:1849-61.
99. Maggi L, Santarlasci V, Capone M, Rossi MC, Querci V, Mazzoni A, et al. Distinctive features of classic and nonclassic (Th17 derived) human Th1 cells. Eur J Immunol. 2012 Dec;42:3180-8.
100. Zielinski CE, Mele F, Aschenbrenner D, Jarrossay D, Ron- chi F, Gattorno M, et al. Pathogen-induced human TH17 cells produce IFN-γ or IL-10 and are regulated by IL-1β. Nature. Nature Publishing Group; 2012 Apr 26;484:514-8.
101. Koenen HJPM, Smeets RL, Vink PM, van Rijssen E, Boots AMH, Joosten I. Human CD25highFoxp3pos regulatory T cells differentiate into IL-17-producing cells. Blood. 2008 Sep 15;112:2340-52.
102. Ayyoub M, Deknuydt F, Raimbaud I, Dousset C, Leveque L, Bioley G, et al. Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgammat. Proc Natl Acad Sci U S A. 2009 May 26;106:8635-40.
103. Beriou G, Costantino CM, Ashley CW, Yang L, Kuchroo VK, Baecher-Allan C, et al. IL-17-producing human peripheral regulatory T cells retain suppressive function. Blood. 2009 Apr 30;113:4240-9.
104. Voo KS, Wang Y-H, Santori FR, Boggiano C, Wang Y-H, Arima K, et al. Identification of IL-17-producing FOXP3+ regulatory T cells in humans. Proc Natl Acad Sci U S A. 2009 Mar 24;106:4793-8.
105. Hardy R, Hayakawa K. B cell development pathways. Annu Rev Immunol. 2001;19:595-621.
106. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood. 2008 Sep 1;112:1570-80.
107. Lanzavecchia A. Antigen-Specific Interaction between T and B Cells. Nature. 1985;314:537-9.
108. Bishop G, Hostager B. B lymphocyte activation by contact-mediated interactions with T lymphocytes. Curr Opin Immunol. 2001 Jun;13:278-85.
109. Yanaba K, Bouaziz J-D, Matsushita T, Magro CM, St Clair EW, Tedder TF. B-lymphocyte contributions to human autoimmune disease. Immunol Rev. 2008 Jun;223:284-99.
110. Kantor AB. The development and repertoire of B-1 cells (CD5 B cells). Immunol Today. 1991;12:389-91.
111. Allman D, Pillai S. Peripheral B cell subsets. Curr Opin Immunol. 2008;20:149-57.
112. Boes M, Prodeus A, Schmidt T, Carroll M, Chen J. A critical role of natural immunoglobulin M in immediate defense against systemic bacterial infection. J Exp Med. 1998 Dec 21;188:2381-6.
113. Baumgarth N, Herman O, Jager G, Brown L, Herzenberg L, Chen J. B-1 and B-2 cell-derived immunoglobulin M antibodies are nonredundant components of the protective response to influenza virus infection. J Exp Med. 2000 Jul 17;192:271-80.
114. Hardy RR. B-1 B Cell Development. J Immunol. 2006 Aug 18;176:2749-54.
115. Zhong X, Gao W, Degauque N, Bai C, Lu Y, Kenny J, et al. Reciprocal generation of Th1/Th17 and T(reg) cells by B1 and B2 B cells. Eur J Immunol. 2007 Sep;37:2400-4.
116. Lydyard PM, Lamour A, MacKenzie LE, Jamin C, Mageed RA, Youinou P. CD5+ B cells and the immune system. Immunol Lett. 1993 Oct;38:159-66.
117. Zhou Z, Tzioufas AG, Notkins AL. Properties and function of polyreactive antibodies and polyreactive antigen-binding cells. J Autoimmun. 2007;29:219-28.
118. Hardy R, Hayakawa K, Shimizu M, Yamasaki K, Kishimoto T. Rheumatoid factor secretion from human Leu-1+ B cells. Science. 1987;236:(80)81-3.
119. Suzuki N, Sakane T, Engleman E. Anti-DNA antibody production by CD5+ and CD5B cells of patients with systemic lupus erythematosus. J Clin Invest. 1990 Jan;85:238-47.
120. Casali P, Burastero S, Nakamura M, Inghirami G, Notkins A. Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science. 1987 Apr 3;236:77-81.
121. Gary-Gouy H, Harriague J, Bismuth G, Platzer C, Schmitt C, Dalloul AH. Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production. Blood. 2002;100:4537-43.
122. Carsetti R, Rosado MM, Wardmann H. Peripheral development of B cells in mouse and man. Immunol Rev. 2004 Feb;197:179-91.
123. Ekerfelt C, Ernerudh J, Solderst G, Vrethem M. CD5 expression on B cells may be an activation marker for secretion of anti-myelin antibodies in patients with polyneuropathy associated with monoclonal gammopathy. Clin Exp Immunol. 1995;101:346-50.
124. Griffin DO, Holodick NE, Rothstein TL. Human B1 cells in umbilical cord and adult peripheral blood express the novel phenotype CD20+ CD27+ CD43+ CD70-. J Exp Med. 2011 Jan 17;208:67-80.
125. Carsetti R, Kohler G, Lamers MC. Transitional B Cells Are the Target of Negative Selection in the B Cell Compartment. J Exp Med. 1995;181:2129-40.
126. Agrawal S, Smith S, Tangye S, Sewell W. Transitional B cell subsets in human bone marrow. Clin Exp Immunol. 2013 Oct;174:53-9.
127. Allman D, Lindsley R, DeMuth W, Rudd K, Shinton S, Hardy R. Resolution of three nonproliferative immature splenic B cell subsets reveals multiple selection points during peripheral B cell maturation. J Immunol. 2001 Dec 15;167:6834-40.
128. Chung JB, Sater RA, Fields ML, Erikson J, Monroe JG. CD23 defines two distinct subsets of immature B cells which differ in their responses to T cell help signals. Int Immunol. 2002 Feb;14:157-66.
129. Petro JB, Gerstein RM, Lowe J, Carter RS, Shinners N, Khan WN. Transitional type 1 and 2 B lymphocyte subsets are differentially responsive to antigen receptor signaling. J Biol Chem. 2002 Dec 13;277:48009-19.
130. Loder F, Mutschler B, Ray R, Paige C, Sideras P, Torres R, et al. B cell development in the spleen takes place in discrete steps and is determined by the quality of B cell receptor-derived signals. J Exp Med. 1999 Jul 5;190:75-89.
131. Sims GP, Ettinger R, Shirota Y, Yarboro CH, Illei GG, Lipsky PE. Identification and characterization of circulating human transitional B cells. Blood. 2005 Jun 1;105:4390-8.
132. Marie-Cardine A, Divay F, Dutot I, Green A, Perdrix A, Boyer O, et al. Transitional B cells in humans: characterization and insight from B lymphocyte reconstitution after hematopoietic stem cell transplantation. Clin Immunol. 2008 Apr;127:14-25.
133. Palanichamy A, Barnard J, Zheng B, Owen T, Quach T, Looney RJ, et al. Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol. 2009;182:5982-93.
134. Suryani S, Fulcher D a, Santner-Nanan B, Nanan R, Wong M, Shaw PJ, et al. Differential expression of CD21 identifies developmentally and functionally distinct subsets of human transitional B cells. Blood. 2010 Jan 21;115:519-29.
135. Martin F, Kearney J. B1 cells: similarities and differences with other B cell subsets. Curr Opin Immunol. 2001 Apr;13:195-201.
136. Pillai S, Cariappa A. The follicular versus marginal zone B lymphocyte cell fate decision. Nat Rev Immunol. 2009 Nov;9:767-77.
137. Cerutti A, Cols M, Puga I. Marginal zone B cells: virtues of innatelike antibody-producing lymphocytes. Nat Rev Immunol. 2013;13:118-32.
138. Oliver AM, Martin F, Kearney JF. IgMhigh CD21high Lymphocytes Enriched in the Splenic Marginal Zone Generate Effector Cells More Rapidly Than the Bulk of Follicular B Cells. J Immunol. 1999;162:7198-207.
139. Cariappa A, Mazo IB, Chase C, Shi HN, Liu H, Li Q, et al. Perisinusoidal B cells in the bone marrow participate in T-independent responses to blood-borne microbes. Immunity. 2005 Oct;23:397-407.
140. Attanavanich K, Kearney J. Marginal Zone, but Not Follicular B Cells, Are Potent Activators of Naive CD4 T Cells. J Immunol. 2004 Jan 5;172:803-11.
141. Kraal G. Antigens take the shuttle. Nat Immunol. 2008 Jan;9:11-2.
142. Cinamon G, Zachariah MA, Lam OM, Foss Jr. FW, Cyster JG. Follicular shuttling of marginal zone B cells facilitates antigen transport. Nat Immunol. 2008;9:54-62.
143. Spencer J, Perry ME, Dunn-Walters DK. Human marginalzone B cells. Immunol Today. 1998 Sep;19:421-6.
144. Wolf S, Dittel B, Hardardottir F, Janeway C. Experimental autoimmune encephalomyelitis induction in genetically B celldeficient mice. J Exp Med. 1996 Dec 1;184:2271-8.
145. Fillatreau S, Sweenie CH, McGeachy MJ, Gray D, Anderton SM. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002 Oct;3:944-50.
146. Mizoguchi E, Mizoguchi A, Preffer F, Bhan A. Regulatory role of mature B cells in a murine model of inflammatory bowel disease. Int Immunol. 2000 May;12:597-605.
147. Mizoguchi A, Mizoguchi E, Takedatsu H, Blumberg RS, Bhan AK. Chronic Intestinal Inflammatory Condition Generates IL-10-Producing Regulatory B Cell Subset Characterized by CD1d Upregulation. Immunity. 2002;16:219-30.
148. Mauri C, Gray D, Mushtaq N, Londei M. Prevention of Arthritis by Interleukin 10-producing B Cells. J Exp Med. 2003;197:489-501.
149. Carter NA, Rosser EC, Mauri C. Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis. Arthritis Res Ther. BioMed Central Ltd; 2012 Jan;14:R32.
150. O’Garra, Howard M. IL-10 Production by CD5 B Cells. Ann N Y Acad Sci. 1992 May 17;651:182-99.
151. Blair PA, Noreña LY, Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity. 2010 Jan 29;32:129-40.
152. Griffin DO, Rothstein TL. A small CD11b(+) human B1 cell subpopulation stimulates T cells and is expanded in lupus. J Exp Med. 2011 Dec 19;208:2591-8.
153. Ding Q, Yeung M, Camirand G, Zeng Q, Akiba H, Yagita H, et al. Regulatory B cells are identified by expression of TIM-1 and can be induced through TIM-1 ligation to promote tolerance in mice. J Clin Invest. 2011;121:3645-56.
154. Iwata Y, Matsushita T, Horikawa M, Dilillo DJ, Yanaba K, Venturi GM, et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood. 2011 Jan 13;117:530-41.
155. Cantaert T, Doorenspleet ME, Francosalinas G, Paramarta JE, Klarenbeek PL, Tiersma Y, et al. Increased numbers of CD5+ B lymphocytes with a regulatory phenotype in spondylarthritis. Arthritis Rheum. 2012 Jun;64:1859-68.
156. Zha B, Wang L, Liu X, Liu J, Chen Z, Xu J, et al. Decrease in proportion of CD19+ CD24(hi) CD27+ B cells and impairment of their suppressive function in Graves’ disease͘. PLoS One͘ 2012 Jan;7:e49835.
157. Kessel A, Haj T, Peri R, Snir A, Melamed D, Sabo E, et al. Human CD19+CD25high B regulatory cells suppress proliferation of CD4+ T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. Autoimmun Rev. 2012;11:670-7.
158. Flores-Borja F, Bosma A, Ng D, Reddy V, Ehrenstein MR, Isenberg DA, et al. CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med. 2013 Feb 20;5:173ra23.
159. Van der Vlugt L, Mlejnek E, Ozir-Fazalalikhan A, Janssen Bonas M, Dijksman T, Labuda L, et al. CD24(hi)CD27(+) B cells from patients with allergic asthma have impaired regulatory activity in response to lipopolysaccharide. Clin Exp Allergy. 2013 Apr;44:517-28.
160. Daien CI, Gailhac S, Mura T, Audo R, Combe B, Hahne M, et al. Regulatory B10 cells are decreased in patients with rheumatoid arthritis and are inversely correlated with disease activity. Arthritis Rheum. 2014;66:2037-46.
161. Liu J, Zhan W, Kim CJ, Clayton K, Zhao H, Lee E, et al. IL10-producing B cells are induced early in HIV-1 infection and suppress HIV-1-specific T cell responses. PLoS One. 2014 Jan;9:e89236.
162. Bouaziz J-D, Calbo S, Maho-Vaillant M, Saussine A, Bagot M, Bensussan A, et al. IL-10 produced by activated human B cells regulates CD4(+) T-cell activation in vitro. Eur J Immunol. 2010 Oct;40:2686-91.
163. Rapoport B, Chazenbalk G, Jaume J, McLachlan S. The thyrotropin (TSH) receptor: interaction with TSH and autoantibodies. Endocr Rev. 1998 Dec;19:673-716.
164. Weetman ͘A. Graves’ disease͘. N Engl J Med͘ 2000;343:1236-48.
165. Chistiakov D. Immunogenetics of Hashimoto’s thyroiditis. J Autoimmune Dis. 2005 Mar 11;2:1.
166. Dayan C, Daniels G. Chronic Autoimmune Thyroiditis. N Engl J Med. 1996;335:99-107.
167. Weetman AP. Determinants of autoimmune thyroid disease. Nat Immunol. 2001 Sep;2:769-70.
168. Menconi F, Marcocci C, Marinò M. Diagnosis and classification of Graves’ disease͘. Autoimmun Rev͘ 2014;13:398-402.
169. Faber J, Wiinberg N, Schifter S, Mehlsen J. Haemodynamic changes following treatment of subclinical and overt hyperthyroidism. Eur J Endocrinol. 2001 Oct 1;145:391-6.
170. Caturegli P, De Remigis A, Rose N. Hashimoto thyroiditis: clinical and diagnostic criteria. Autoimmun Rev. Elsevier B.V.; 2014;13:391-7.
171. Tomer Y, Huber A. The etiology of autoimmune thyroid disease: a story of genes and environment. J Autoimmun. 2009;32:231-9.
172. Vanderpump MP. The epidemiology of thyroid disease. Br Med Bull. 2011 Jan;99:39-51.
173. Brix TH, Hegedüs L. Twin studies as a model for exploring the aetiology of autoimmune thyroid disease. Clin Endocrinol (Oxf). 2012 Apr;76:457-64.
174. Brix TH, Kyvik KO, Hegedu L. A Population-Based Study of Chronic Autoimmune Hypothyroidism in Danish Twins. J Clin Endocrinol Metab. 2000;85:536-9.
175. Knudsen N, Jùrgensen T, Rasmussen S, Christiansen E, Perrild H. The prevalence of thyroid dysfunction in a population with borderline iodine deficiency. Clin Endocrinol (Oxf). 1999;51:361-7.
176. Effraimidis G, Wiersinga WM. Mechanisms in endocrinology: autoimmune thyroid disease: old and new players. Eur J Endocrinol. 2014 Jun;170:R241-R252.
177. Brix TH, Knudsen GPS, Kristiansen M, Kyvik KO, Orstavik KH, Hegedüs L. High frequency of skewed X-chromosome inactivation in females with autoimmune thyroid disease: a possible explanation for the female predisposition to thyroid autoimmunity. J Clin Endocrinol Metab. 2005 Nov;90:5949-53.
178. Brix TH, Christensen K, Holm N V, Harvald B, Hegedüs L. A population-based study of Graves’ disease in Danish twins͘. Clin Endocrinol (Oxf). 1998;48:397-400.
179. Brix TH, Kyvik KO, Christensen K, Twin TD. Evidence for a Major Role of Heredity in Graves’ Disease : Population-Based Study of Two Danish Twin Cohorts. J Clin Endocrinol Metab. 2001;86:930-4.
180. Weetman AP. Autoimmune thyroid disease: propagation and progression. Eur J Endocrinol. 2003;148:1-9.
181. Tomer Y, Hasham A, Davies TF, Stefan M, Concepcion E, Keddache M, et al. Fine mapping of loci linked to autoimmune thyroid disease identifies novel susceptibility genes. J Clin Endocrinol Metab. 2013 Jan;98:E144-E152.
182. Bülow Pedersen I, Knudsen N, Jørgensen T, Perrild H, Ovesen L, Laurberg P. Large differences in incidences of overt hyperand hypothyroidism associated with a small difference in iodine intake: a prospective comparative register-based population survey. J Clin Endocrinol Metab. 2002 Oct;87:4462-9.
183. Vejbjerg P, Knudsen N, Perrild H, Laurberg P, Carlé A, Pedersen IB, et al. Lower prevalence of mild hyperthyroidism related to a higher iodine intake in the population: prospective study of a mandatory iodization programme. Clin Endocrinol (Oxf). 2009 Sep;71:440-5.
184. Andersen S, Iversen F, Terpling S, Pedersen KM, Gustenhoff P, Laurberg P. More hypothyroidism and less hyperthyroidism with sufficient iodine nutrition compared to mild iodine deficiency--a comparative population-based study of older people. Maturitas. 2009 Oct 20;64:126-31.
185. Pedersen IB, Laurberg P, Knudsen N, Jørgensen T, Perrild H, Ovesen L, et al. An increased incidence of overt hypothyroidism after iodine fortification of salt in Denmark: a prospective population study. J Clin Endocrinol Metab. 2007 Aug;92:3122-7.
186. Brix TH, Hansen PS, Kyvik KO, Hegedüs L. Cigarette Smoking and Risk of Clinically Overt Thyroid Disease. Arch Intern Med. 2000;160:661-6.
187. Andersen SL, Olsen J, Wu C Sen, Laurberg P. Smoking reduces the risk of hypothyroidism and increases the risk of hyperthyroidism: evidence from 450,842 mothers giving birth in Denmark. Clin Endocrinol (Oxf). 2014 Feb;80:307-14.
188. Hegedüs L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves’ ophthalmopathy͘. J Endocrinol Invest. 2004;27:265-71.
189. Carlé A, Pedersen IB, Knudsen N, Perrild H, Ovesen L, Rasmussen LB, et al. Moderate alcohol consumption may protect against overt autoimmune hypothyroidism: a populationbased case-control study. Eur J Endocrinol. 2012 Oct;167:483-90.
190. Carlé A, Bülow Pedersen I, Knudsen N, Perrild H, Ovesen L, Rasmussen LB, et al. Graves’ hyperthyroidism and moderate alcohol consumption: evidence for disease prevention. Clin Endocrinol (Oxf). 2013 Jul;79:111-9.
191. Segundo C, Rodríguez C, Aguilar M, García-Poley A, Gavilán I, Bellas C, et al. Differences in thyroid-infiltrating B lymphocytes in patients with Graves’ disease: relationship to autoantibody detection. Thyroid. 2004 May;14:337-44.
192. Wang SH, Baker JR. The role of apoptosis in thyroid autoimmunity. Thyroid. 2007 Oct;17:975-9.
193. Ben-Skowronek I, Sierocinska-Sawa J, Szewczyk L, Korobowicz E. Interaction of lymphocytes and thyrocytes in Graves’ disease and nonautoimmune thyroid diseases in immunohistochemical and ultrastructural investigations. Horm Res. 2009 Jan;71:350-8.
194. Armengol MP, Juan M, Lucas-Martin A, Jaraquemada D, Gallart T, Pujol-Borrell R. Thyroid Autoimmune Disease: Demonstration of thyroid antigen-specific B cells and recombination-activating gene expression in chemokine-containing active intrathyroidal germinal centers. Am J Pathol. 2001;159:861-73.
195. Vinuesa CG, Sanz I, Cook MC. Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol. 2009 Dec;9:845-57.
196. Rapoport B, Mclachlan SM. Thyroid autoimmunity. J Clin Invest. 2001;108:1253-9.
197. Latrofa F, Chazenbalk GD, Pichurin P, Chen C-R, McLachlan SM, Rapoport B. Affinity-enrichment of thyrotropin receptor autoantibodies from Graves’ patients and normal individuals provides insight into their properties and possible origin from natural antibodies. J Clin Endocrinol Metab. 2004 Sep;89:4734-45.
198. Ajjan R, Weetman A. Techniques to quantify TSH receptor antibodies. Nat Clin Pract Endocrinol Metab. 2008 Aug;4:461-8.
199. Rees Smith B, Sanders J, Evans M, Tagami T, Furmaniak J. TSH Receptor Autoantibody Interactions. Horm Metab Res. 2009 May 20;41:448-55.
200. Morshed SA, Latif R, Davies TF. Delineating the autoimmune mechanisms in Graves’ disease͘. Immunol Res͘ 2012 Dec;54:191-203.
201. Rapoport B, McLachlan SM. The thyrotropin receptor in Graves’ disease͘ Thyroid͘ 2007 Oct;17:911-22.
202. Mizutori Y, Chen C-R, Latrofa F, McLachlan SM, Rapoport B. Evidence that shed thyrotropin receptor A subunits drive affinity maturation of autoantibodies causing Graves’ disease͘. J Clin Endocrinol Metab. 2009 Mar;94:927-35.
203. Chen C-R, Pichurin P, Nagayama Y, Latrofa F, Rapoport B, McLachlan SM. The thyrotropin receptor autoantigen in Graves disease is the culprit as well as the victim. J Clin Invest. 2003;111:1897-904.
204. Roura-Mir C, Catalfamo M, Sospedra M, Alcalde L, PujolBorrell R, Jaraquemada D. Single-cell analysis of intrathyroidal lymphocytes shows differential cytokine expression in Hashimoto’ s and Graves’ disease͘. Eur J Immunol͘ 1997;27:3290-302.
205. Heuer M, Aust G, Ode-Hakim S, Scherbaum WA. Different Cytokine mRN Profiles in Graves’ Disease, Hashimoto's Thyroiditis, and Nonautoimmune Thyroid Disorders Determined by Quantitative Reverse Transcriptase Polymerase Chain Reaction (RT-PCR). Thyroid. 1996 Apr;6:97-106.
206. Nagayama Y, Mizuguchi H, Hayakawa T, Niwa M, McLachlan S, Rapoport B. Prevention of Autoantibody-Mediated Graves’-Like Hyperthyroidism in Mice with IL-4, a Th2 Cytokine. J Immunol. 2003 Apr 1;170:3522-7.
207. Fiorentino D, Zlotnik A, Vieira P, Mosmann T, Howard M, Moore K, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol. 1991 May 15;146:3444-51.
208. Racke MK, Bonomo A, Scott DE, Cannella B, Levine A, Raine CS, et al. Cytokine-induced immune deviation as a therapy for Inflammatory Autoimmune Disease. J Exp Med. 1994;180:1961-6.
209. Stassi G, Di Liberto D, Todaro M, Zeuner A, Ricci-Vitiani L, Stoppacciaro A, et al. Control of target cell survival in thyroid autoimmunity by T helper cytokines via regulation of apoptotic proteins. Nat Immunol. 2000 Dec;1:483-8.
210. Weetman A, McGregor A. Autoimmune thyroid disease: further developments in our understanding. Endocr Rev. 1994 Dec;15:788-830.
211. Lund FE. Cytokine-producing B lymphocytes—key regulators of immunity. Curr Opin Immunol. 2008;20:332-8.
212. Bao Y, Cao X. The immune potential and immunopathology of cytokine-producing B cell subsets: A comprehensive review. J Autoimmun. Elsevier Ltd; 2014 Apr 30;10.1016.
213. Hammond L, Lowdell M, Cerrano P, Goode A, Bottazzo G, Mirakian R. Analysis of apoptosis in relation to tissue destruction associated with Hashimoto’s autoimmune thyroiditis͘ J Pathol. 1997;182:138-44.
214. Flynn J, Conaway D, Cobbold S, Waldmann H, Kong Y. Depletion of L3T4+ and Lyt-2+ cells by rat monoclonal antibodies alters the development of adoptively transferred experimental autoimmune thyroiditis. Cell Immunol. 1989 Sep;122:377-90.
215. Stassi G, Zeuner A, Di Liberto D, Todaro M, Ricci-Vitiani L, De Maria R. Fas-FasL in Hashimoto’ s Thyroiditis. J Clin Immunol. 2001;21:19-23.
216. Peters P, Borst J, Oorschot V, Fukuda M, Krähenbühl O, Tschopp J, et al. Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. J Exp Med. 1991 May 1;173:1099-109.
217. Mackenzie A, Schwartz A, Friedman E, Davies T. Intrathyroidal T Cell Clones from Patients with Autoimmune thyroid disease. J Clin Endocrinol Metab. 1987;64:818-24.
218. Wu Z, Podack E, McKenzie J, Olsen K, Zakarija M. Perforin expression by thyroid-infiltrating T cells in autoimmune thyroid disease. Clin Exp Immunol. 1994 Dec;98:470-7.
219. Ehlers M, Thiel A, Bernecker C, Porwol D, Papewalis C, Willenberg HS, et al. Evidence of a combined cytotoxic thyroglobulin and thyroperoxidase epitope-specific cellular immunity in Hashimoto’s thyroiditis͘ J Clin Endocrinol Metab͘ 2012 Apr;97:1347-54.
220. Ashkenazi A, Dixit V. Death receptors: signaling and modulation. Science. 1998 Aug 28;281:1305-8.
221. Giordano C, Stassi G, De Maria R, Todaro M, Richiusa P, Papoff G, et al. Potential Involvement of Fas and its ligand in the pathogenesis of Hashimoto’s thyroiditis͘ Science͘ 1997;275:960-4.
222. Mitsiades N, Poulaki V, Kotoula V, Mastorakos G, Tseleni-balafouta S, Koutras D, et al. Fas/Fas ligand up-regulation and Bcl-2 down-regulation may be significant in the pathogenesis of Hashimoto’s thyroiditis͘ J Clin Endocrinol Metab͘ 1998;83:2199-203.
223. Borgerson K, Bretz J, Baker J. The Role of Fas-mediated apoptosis in Thyroid Autoimmune disease. Autoimmunity. 1999;30:251-64.
224. De Maria R, Testi R. Fas-FasL interactions: a common pathogenetic mechanism in organ-specific autoimmunity. Immunol Today. 1998 Mar;19:121-5.
225. Kawakami A, Eguchi K, Tsuboi NM, Kawabe Y, Medicine I, Hospital NZ. Thyroid-Stimulating Inhibits Fas antigen-mediated apoptosis of human thyrocytes in Vitro. Endocrinology. 1996;137:3163-9.
226. Stassi G, Todaro M, Bucchieri F, Farina F, Zummo G, Maria R De, et al. Fas/Fas Ligand-Driven T Cell Apoptosis as a Consequence of Ineffective Thyroid Immunoprivilege in Hashimoto’s Thyroiditis͘ J Immunol͘ 1999;162:263-7.
227. Bogner U, Schleusener H, Wall J. Antibody-Dependent Cell Mediated Cytotoxicity against Human Thyroid Cells in Hashimoto’s Thyroiditis but Not Graves' Disease͘ J Clin Endocrinol Metab. 1984;59:734-8.
228. Guo J, Jaume JC, Rapoport B, McLachlan SM. Recombinant Thyroid Peroxidase-Specific Fab Converted to Immunoglobulin G (IgG) Molecules : Evidence for Thyroid Cell Damage by IgG1, but Not IgG4, Autoantibodies. J Clin Endocrinol Metab. 1997;82:925-31.
229. Weetman A, Bright-Thomas R, Freeman M. Regulation of interleukin-6 release by human thyrocytes. J Endocrinol. 1990 Nov;127:357-61.
230. Weetman A, Bennett G, Wong W. Thyroid follicular cells produce interleukin-8. J Clin Endocrinol Metab. 1992;75:328-30.
231. Nielsen CH, Brix TH, Leslie RGQ, Hegedüs L. A role for autoantibodies in enhancement of pro-inflammatory cytokine responses to a self-antigen, thyroid peroxidase. Clin Immunol. Elsevier Inc.; 2009 Nov;133:218-27.
232. Tomer Y. Anti-thyroglobulin Autoantibodies in Autoimmune Thyroid Diseases : Cross-Reactive or Pathogenic ? Clin Immunol Immunopathol. 1997;82:3-11.
233. Del Prete G, Tiri A, Mariottit S, Pincherat A, Ricci M, Cattedra R, et al. Enhanced production of y-interferon by thyroidderived T cell clones from patients with Hashimoto’ s thyroiditis. Clin Exp Immunol. 1987;69:323-31.
234. Ajjan R, Watson P, Mcintosh R, Weetman A. Intrathyroidal cytokine gene expression in Hashimoto’s thyroiditis. Clin Exp Immunol. 1996 Sep;105:523-8.
235. Guo J, Rapoport B, McLachlan S. Balance of Th1/Th2 cytokines in thyroid autoantibody synthesis in vitro. Autoimmunity. 1999 Jan;30:1-9.
236. Colin I, Isaac J, Dupret P, Ledant T, D’Hautcourt J͘ Functional lymphocyte subset assessment of the Th1/Th2 profile in patients with autoimmune thyroiditis by flowcytometric analysis of peripheral lymphocytes. J Biol Regul Homeost Agents. 2004;18:72-6.
237. Weetman A. The potential immunological role of the thyroid cell in autoimmune thyroid disease. Thyroid. 1994;4:493-9.
238. Todd I, Pujol-Borrell R, Hammond L, Bottazzo G, Feldmann M. Interferon-y induces HLA-DR expression by thyroid epithelium. Clin Exp Immunol. 1985;61:265-73.
239. Marelliberg FM, Weetman A, Frasca L, Deacock SJ, Imami N, Lombardi G, et al. Antigen Presentation by Epithelial Cells Induces Anergic Immunoregulatory CD45RO+ T cells and Deletion of CD45RA+ T cells. J Immunol. 1997;159:5853-61.
240. Ajjan R, Watson P, Weetman A. Ribonucleic Acid in the Thyroid of Patients with Autoimmune Thyroid Disease *. J Clin Endocrinol Metab. 1997;82:666-9.
241. Kemp EH, Metcalfe RA, Smith KA, Woodroofe MN, Watson PF, Weetman AP. Detection and localization of chemokine gene expression in autoimmune thyroid disease. Clin Endocrinol (Oxf). 2003;59:207-13.
242. Fiorentino D, Bond M, Mosmann T. TWO TYPES OF MOUSE T HELPER CELL IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989;170:2081-95.
243. De Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: An autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209-20.
244. Chatila T, Silverman L, Miller R, Geha R. Mechanisms of T cell activation by the calcium ionophore ionomycin. J Immunol. 1989 Aug 15;143:1283-9.
245. Medzhitov R, Janeway CJ. Innate Immunity. N Engl J Med. 2000;343:338-44.
246. Jørgensen K, Skrede M, Cruciani V, Mikalsen S-O, Slipicevic A, Flørenes VA. Phorbol ester phorbol-12-myristate-13acetate promotes anchorage-independent growth and survival of melanomas through MEK-independent activation of ERK1/2. Biochem Biophys Res Commun. 2005 Apr 1;329:266-74.
247. Aderem A, Ulevitch RJ. Toll-like receptors in the induction of the innate immune response. Nature. 2000;406:782-7.
248. Assenmacher M, Löhning M, Radbruch A. Detection and isolation of cytokine secreting cells using the cytometric cytokine secretion assay. Curr Protoc Immunol. 2002 Feb;Chapter 6:Unit 6.27.
249. Wagner M, Rajasekaran A, Hanzel D, Mayor S, RodriguezBoulan E. Brefeldin A causes structural and functional alterations of the trans-Golgi network of MDCK cells. J Cell Sci. 1994 Apr;107:933-43.
250. Fujiwara T, Yokotas S, Takatsukig A, Ikeharan Y. Brefeldin A Causes Disassembly of the Golgi Complex and Accumulation of Secretory Proteins in the Endoplasmic Reticulum. J Biol Chem. 1988;263:18545-52.
251. Adorini L, Ullrich S, Appella E, Fuchs S. Inhibition by brefeldin A of presentation of exogenous protein antigens to MHC class II-restricted T cells. Nature. 1990;346:63-6.
252. Yewdell J, Bennink J. Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes. Science. 1989 Jun 2;244:1072-5.
253. Liu S, Tobias R, McClure S, Styba G, Shi Q, Jackowski G. Removal of Endotoxin from Recombinant Protein Preparations. Clin Biochem. 1997;30:455-63.
254. Hoshino K, Takeuchi O, Kawai T, Sanjo H, Ogawa T, Takeda Y, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol. 1999 Apr 1;162:3749-52.
255. Medzhitov R. Toll-like receptors and innate immunity. Nat Rev Immunol. 2001 Nov;1:135-45.
256. Chen L-Y, Zuraw BL, Zhao M, Liu F-T, Huang S, Pan ZK. Involvement of protein tyrosine kinase in Toll-like receptor 4mediated NF-kappa B activation in human peripheral blood monocytes. Am J Physiol Lung Cell Mol Physiol. 2003 Apr;284:L607-L613.
257. Matsukawa A, Yoshinaga M. Sequential generation of cytokines during the initiative phase of inflammation, with reference to neutrophils. Inflamm Res. 1998 Oct;47:S137-S144.
258. Mukherjee S, Chen L-Y, Papadimos TJ, Huang S, Zuraw BL, Pan ZK. Lipopolysaccharide-driven Th2 cytokine production in macrophages is regulated by both MyD88 and TRAM. J Biol Chem. 2009 Oct 23;284:29391-8.
259. Byrne A, Reen D. Lipopolysaccharide Induces Rapid Production of IL-10 by Monocytes in the Presence of Apoptotic Neutrophils. J Immunol. 2002 Feb 15;168:1968-77.
260. Nielsen CH, Galdiers MP, Hedegaard CJ, Leslie RGQ. The self-antigen, thyroglobulin, induces antigen-experienced CD4+T cells from healthy donors to proliferate and promote production of the regulatory cytokine, interleukin-10, by monocytes. Immunology. 2009;129:291-9.
261. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, et al. Quantitative Expression of Toll-Like Receptor 1-10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG Oligodeoxynucleotides. J Immunol. 2002 May 1;168:4531-7.
262. Bourke E, Bosisio D, Golay J, Polentarutti N, Mantovani A. The toll-like receptor repertoire of human B lymphocytes : inducible and selective expression of TLR9 and TLR10 in normal and transformed cells. Blood. 2003;102:956-63.
263. Dasari P, Nicholson IC, Hodge G, Dandie GW, Zola H. Expression of toll-like receptors on B lymphocytes. Cell Immunol. 2005;236:140-5.
264. Shin H, Zhang Y, Jagannathan M, Hasturk H, Kantarci A, Liu H, et al. B cells from periodontal disease patients express surface Toll-like receptor 4. J Leukoc Biol. 2009 Apr;85:648-55.
265. Jagannathan M, McDonnell M, Liang Y, Hasturk H, Hetzel JT, Rubin D, et al. Toll-like receptors regulate B cell cytokine production in patients with diabetes. Diabetologia. 2010;53:1461-71.
266. Mita Y, Dobashi K, Endou K, Kawata T, Shimizu Y, Nakazawa T, et al. Toll-like receptor 4 surface expression on human monocytes and B cells is modulated by IL-2 and IL-4. Immunol Lett. 2002 Apr 1;81:71-5.
267. Ganley-leal LM, Liang Y, Jagannathan-bogdan M, Farraye F, Nikolajczyk BS. Differential regulation of TLR4 expression in human B cells and monocytes. Mol Immunol. 2010;48:82-8.
268. Jagannathan M, Hasturk H, Liang Y, Shin H, Hetzel JT, Kantarci A, et al. TLR cross-talk specifically regulates cytokine production by B cells from chronic inflammatory disease patients. J Immunol. 2009 Dec 1;183:7461-70.
269. Gray D, Gray M. What are regulatory B cells? Eur J Immunol. 2010 Oct;40:2677-9.
270. Bouaziz J-D, Yanaba K, Tedder TF. Regulatory B cells as inhibitors of immune responses and inflammation. Immunol Rev. 2008 Aug;224:201-14.
271. Bernasconi NL, Onai N, Lanzavecchia A. A role for Tolllike receptors in acquired immunity: up-regulation of TLR9 by BCR triggering in naive B cells and constitutive expression in memory B cells. Blood. 2003 Jun 1;101:4500-4.
272. Akira S, Takeda K, Kaisho T. Toll-like receptors : critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675-80.
273. Klinker MW, Lundy SK. Multiple mechanisms of immune suppression by B lymphocytes. Mol Med. 2012 Jan;18:123-37.
274. Noh G, Lee JH. Regulatory B cells and allergic diseases. Allergy Asthma Immunol Res. 2011 Jul;3:168-77.
275. Dono M, Cerruti G, Zupo S. The CD5+ B-cell. Int J Biochem Cell Biol. 2004 Nov;36:2105-11.
276. Casali P, Notkins AL. PROBING THE HUMAN B-CELL REPERTOIRE WITH EBV : Polyreactive ntibodies and CD5+ B Lymphocytes. Annu Rev Immunol. 1989;7:513-35.
277. Mannoor K, Xu Y, Chen C. Natural autoantibodies and associated B cells in immunity and autoimmunity. Autoimmunity. 2013;46:138-47.
278. Nielsen CH, Leslie RGQ, Jepsen BS, Kazatchkine MD, Kaveri S V, Fischer E. Natural autoantibodies and complement promote the uptake of a self antigen, human thyroglobulin, by B cells and the proliferation of thyroglobulinreactive CD4+ T cells in healthy individuals. Eur J Immunol. 2001;31:2660-8.
279. Schroeder K, Herrmann M, Winkler TH. The role of somatic hypermutation in the generation of pathogenic antibodies in SLE. Autoimmunity. 2013 Mar;46:121-7.
280. McIntosh R, Watson P, Weetman A. Somatic hypermutation in autoimmune thyroid disease. Immunol Rev. 1998 Apr;162:219-31.
281. Kay R, Rosten PM, Humphries RK. CD24, a signal transducer modulating B cell activation responses, is a very short peptide with a glycosyl phosphatidylinositol membrane anchor. J Immunol. 1991 Aug 15;147:1412-6.
282. Liu Y, Jones B, Aruffo A, Sullivan K, Linsley P, Janeway C. Heat-stable antigen is a costimulatory molecule for CD4 T cell growth. J Exp Med. 1992 Feb 1;175:437-45.
283. Hough M, Rosten P, Sexton T, Kay R, Humphries RK. Mapping of CD24 and homologous sequences to multiple chromosomal loci. Genomics. 1994;22:154-61.
284. De Souza J, Oriss TB, O’Malley KJ, Ray, Kane LP͘ T cell Ig and mucin 1 (TIM-1) is expressed on in vivo-activated T cells and provides a costimulatory signal for T cell activation. Proc Natl Acad Sci U S A. 2005 Nov 22;102:17113-8.
285. Kuchroo VK, Dardalhon V, Xiao S, Anderson AC. New roles for TIM family members in immune regulation. Nat Rev Immunol. 2008;8:577-80.
286. Ueno T, Habicht A, Clarkson MR, Albin MJ, Yamaura K, Boenisch O, et al. The emerging role of T cell Ig mucin 1 in alloimmune responses in an experimental mouse transplant model. J Clin Invest. 2008;118:742-51.
287. Degauque N, Mariat C, Kenny J, Zhang D, Gao W, Vu MD, et al. Immunostimulatory Tim-1 specific antibody deprograms Tregs and prevents transplant tolerance in mice. J Clin Invest. 2008;118:735-41.
288. Brisslert M, Bokarewa M, Larsson P, Wing K, Collins LV, Tarkowski A. Phenotypic and functional characterization of human CD25+ B cells. Immunology. 2006 Apr;117:548-57.
289. Amu S, Brisslert M. Phenotype and function of CD25-expressing B lymphocytes isolated from human umbilical cord blood. Clin Dev Immunol. 2011 Jan;2011:481948.
290. Amu S, Strömberg K, Bokarewa M, Tarkowski A, Brisslert M. CD25-expressing B-lymphocytes in rheumatic diseases. Scand J Immunol. 2007 Mar;65:182-91.
291. De Andrés C, Tejera-Alhambra M, Alonso B, Valor L, Teijeiro R, Ramos-Medina R, et al. New regulatory CD19(+)CD25(+) B-cell subset in clinically isolated syndrome and multiple sclerosis relapse. Changes after glucocorticoids. J Neuroimmunol. Elsevier B.V.; 2014 May 15;270:37-44.
292. Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol. 2007 Dec;8:1353-62.
293. Griffin DO, Rothstein TL͘ Human “orchestrator” CD11b+ B1 cells spontaneously secrete IL-10 and regulate T cell activity. Mol Med. 2012 Jan;18:1003-8.
294. Hovsepian E, Penas F, Siffo S, Mirkin GA, Goren NB. IL-10 inhibits the NF-κB and ERK/MAPK-mediated production of pro-inflammatory mediators by up-regulation of SOCS-3 in Trypanosoma cruzi-infected cardiomyocytes. PLoS One. 2013 Jan;8:e79445.
295. Blackwell T, Christman J. The role of nuclear factor-kappa B in cytokine gene regulation. Am J Respir Cell Mol Biol. 1997 Jul;17:3-9.
296. Tak PP, Firestein GS. NFκB : a key role in inflammatory diseases. J Clin Invest. 2001;107:7-11.
297. Lin W, Cerny D, Chua E, Duan K, Yi JTJ, Shadan NB, et al. Human Regulatory B Cells Combine Phenotypic and Genetic Hallmarks with a Distinct Differentiation Fate. J Immunol. 2014 Jul 30;193:2258-66.
298. Guermonprez P, Valladeau J, Zitvogel L, Théry C, Amigorena S. Antigen presentation and T cell stimulation by dendritic cells. Annu Rev Immunol. 2002 Jan;20:621-67.
299. Randolph G, Jakubzick C, Qu C. Antigen presentation by monocytes and monocyte-derived cells. Curr Opin Immunol. 2008;20:52-60.
300. Scala G, Oppenheim J. Antigen presentation by human monocytes: evidence for stimulant processing and requirement for interleukin 1. J Immunol. 1983 Sep;131:1160-6.
301. Tosato G, Jones K. Interleukin-1 induces interleukin-6 production in peripheral blood monocytes. Blood. 1990;75:1305-10.
302. Beck L, Roth R, Spiegelberg H. Comparison of Monocytes and B Cells for Activation of Human T Helper Cell Subsets. Clin Immunol Immunopathol. 1996;78:56-60.
303. Constant S, Schweitzer N, West J, Ranney P, Bottomly K. B Lymphocytes can be competent antigen-presenting cells for priming CD4+ T cells to protein antigens in vivo. J Immunol. 1995;155:3734-41.
304. Rodríguez-Pinto D. B cells as antigen presenting cells. Cell Immunol. 2005 Dec;238:67-75.
305. Guo J, Wang Y, Rapoport B, McLachlan SM. Evidence for antigen presentation to sensitized T cells by thyroid peroxidase (TPO)-specific B cells in mice injected with fibroblasts coexpressing TPO and MHC class II. Clin Exp Immunol. 2000;119:38-46.
306. Sundstedt A, Rosendahl A, Kalland T, Rooijen N Van, Dohlsten M. Immunoregulatory Role of IL-10 During Superantigen-Induced Hyporesponsives In Vivo. J Immunol. 1997;158:180-6.
307. Ding L, Linsley PS, Huang L, Shevach EM, Germain N. IL-10 Inhibits Macrophage Costimulatory Activity by Selectively Inhibiting the Upregulation of B7 Expression. J Immunol. 1993;151:1224-34.
308. Glick AB, Wodzinski A, Fu P, Levine AD, Wald DN. Impairment of regulatory T-cell function in autoimmune thyroid disease. Thyroid. 2013 Jul;23:871-8.
309. Pan D, Shin Y-H, Gopalakrishnan G, Hennessey J, De Groot LJ͘ Regulatory T cells in Graves’ disease͘ Clin Endocrinol (Oxf). 2009 Oct;71:587-93.
310. Marazuela M, Garcia-Lopez M, Figueroa-Vega N, de la Fuente H, Alvarado-Sanchez B, Monsivais-Urenda A, et al. Regulatory T Cells in Human Autoimmune Thyroid Disease. J Clin Endocrinol Metab. 2006;91:3639-46.
311. Nakano A, Watanabe M, Iida T, Kuroda S, Matsuzuka F, Miyauchi A, et al. Apoptosis-induced decrease of intrathyroidal CD4+CD25+ Regulatory T Cells in Autoimmune Thyroid Diseases. Thyroid. 2007;17:25-31.
312. McAleer JP, Liu B, Li Z, Ngoi S-M, Dai J, Oft M, et al. Potent intestinal Th17 priming through peripheral lipopolysaccharide-based immunization. J Leukoc Biol. 2010 Jul;88:21-31.
313. Evans HG, Suddason T, Jackson I, Taams LS, Lord GM. Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes. Proc Natl Acad Sci U S A. 2007 Oct 23;104:17034-9.
314. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity. 2006 Feb;24:179-89.
315. Marie JC, Letterio JJ, Gavin M, Rudensky AY. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med. 2005 Apr 4;201:1061-7.
316. Yang XO, Pappu B, Nurieva R, Akimzhanov A, Soon H, Chung Y, et al. Th17 lineage differentiation is programmed by orphan nuclear receptors RORa and RORy. Immunity. 2008;28:29-39.
317. De Jong E, Suddason T, Lord G. Translational mini-review series on Th17 cells: development of mouse and human Thelper 17 cells. Clin Exp Immunol. 2010 Feb;159:148-58.
318. Mane VP, Heuer MA, Hillyer P, Navarro MB, Rabin RL. Systematic method for determining an ideal housekeeping gene for real-time PCR analysis. J Biomol Tech. 2008 Dec;19:342-7.
319. Ryder LR, Woetmann A, Madsen HO, Ødum N, Ryder LP, Bliddal H, et al. Expression of full-length and splice forms of FoxP3 in rheumatoid arthritis. Scand J Rheumatol. 2010 Aug;39:279-86.
320. Nielsen CH, Hegedüs L, Leslie RGQ. Autoantibodies in autoimmune thyroid disease promote immune complex formation with self antigens and increase B cell and CD4+ T cell proliferation in response to self antigens. Eur J Immunol. 2004;34:263-72.
321. Nielsen CH, Moeller AC, Hegedüs L, Bendtzen K, Leslie RGQ. Self-Reactive CD4+ T Cells and B Cells in the Blood in Health and Autoimmune Disease: Increased Frequency of Thyroglobulin-Reactive Cells in Graves’ Disease͘ J Clin Immunol. 2006;26:126-37.
322. Nielsen C, Hegedüs L, Rieneck K, Moeller A, Leslie R, Bendtzen K. Production of interleukin (IL)-5 and IL-10 accompanies T helper cell type 1 (Th1) cytokine responses to a major thyroid self-antigen, thyroglobulin, in health and autoimmune thyroid disease. Clin Exp Immunol. 2007 Feb;147:287-95.
323. Weiss I, Davies TF. Inhibition of immunoglobulin-secreting cells by antithyroid drugs. J Clin Endocrinol Metab. 1981 Dec;53:1223-8.
324. Humar M, Dohrmann H, Stein P, Andriopoulos N, Goebel U, Roesslein M, et al. Thionamides Inhibit the Transcription Factor Nuclear Factor-kappa B by Suppression of Rac1 and Inhibitor of kappaB Kinase alpha. J Pharmacol Exp Ther. 2008;324:1037-44.
325. Volpé R. The immunomodulatory effects of anti-thyroid drugs are mediated via actions on thyroid cells, affecting thyrocyte-immunocyte signalling: a review. Curr Pharm Des. 2001 Apr;7:451-60.
326. Wang R-X, Yu C-R, Dambuza IM, Mahdi RM, Dolinska MB, Sergeev Y V, et al. Interleukin-35 induces regulatory B cells that suppress autoimmune disease. Nat Med. 2014 Jun;20:633-41.
327. Shen P, Roch T, Lampropoulou V, O’Connor R, Stervbo U, Hilgenberg E, et al. IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. Nature. 2014 Mar 20;507:366-70.
328. Patel DD, Lee DM, Kolbinger F, Antoni C. Effect of IL-17A blockade with secukinumab in autoimmune diseases. Ann Rheum Dis. 2013 Apr;72:2116-2123.
329. Kellner H. Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potential. Ther Adv Musculoskelet Dis. 2013 Jun;5:141-52.
330. Isono F, Fujita-Sato S, Ito S. Inhibiting RORγt/Th17 axis for autoimmune disorders. Drug Discov Today. 2014 Aug;19:1205-11.